RxDoctor Payments Data

Pradeep Gujja, MD

Cardiovascular Disease · Springfield, OHNPI 1649465600

Payments from drug & device makers

$31,933in general payments, 2019–2025

Across 183 payments — averaging $174.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
  • Janssen Research & Development, LLC$10K
  • Medtronic$2K
  • Medical Device Business Services, Inc.$2K
  • Biosense Webster, Inc.$2K
  • Boston Scientific$2K
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$6,16363%
  • Food & beverage$3,54437%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,933 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$265,273
Medicare patients
586
Services billed
3,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$56,150
XareltoRivaroxaban37$29,839
MultaqDronedarone Hcl18$14,233
EntrestoSacubitril/Valsartan12$11,221
Dofetilide24$3,515
Amiodarone Hcl93$2,034
Metoprolol Succinate140$1,948
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,788
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$1,155
Midodrine Hcl23$1,044
ClopidogrelClopidogrel Bisulfate126$898
Losartan Potassium30$309
Metoprolol Tartrate57$299
Carvedilol40$267
Warfarin Sodium19$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$539$29,83937 claims
Sanofi-aventis U.S. LLCMultaq$101$14,23318 claims
NovartisEntresto$217$11,22112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →